Prevalence and incidence of hypoglycaemia in 532,542 people with Type 2 diabetes on oral therapies and insulin: a systematic review and meta-analysis of population based studies
posted on 2015-05-26, 12:33authored byChloe L. Edridge, Alison J. Dunkley, Danielle H. Bodicoat, Tanith C. Rose, Laura J. Gray, Melanie J. Davies, Kamlesh Khunti
Objective: To collate and evaluate the current literature reporting the prevalence and
incidence of hypoglycaemia in population based studies of type 2 diabetes.
Research design and methods: Medline, Embase and Cochrane were searched up
to February 2014 to identify population based studies reporting the proportion of
people with type 2 diabetes experiencing hypoglycaemia or rate of events
experienced. Two reviewers independently screened studies for eligibility and
extracted data for included studies. Random effects meta-analyses were carried out
to calculate the prevalence and incidence of hypoglycaemia.
Results: 46 studies (n=532,542) met the inclusion criteria. Prevalence of
hypoglycaemia was 45% (95%CI 0.34,0.57) for mild/moderate and 6% (95%CI,
0.05,0.07) for severe. Incidence of hypoglycaemic episodes per person-year for
mild/moderate and for severe was 19 (95%CI 0.00, 51.08) and 0.80 (95%CI
0.00,2.15), respectively. Hypoglycaemia was prevalent amongst those on insulin; for
mild/moderate episodes the prevalence was 50% and incidence 23 events per
person-year, and for severe episodes the prevalence was 21% and incidence 1
event per person-year. For treatment regimes that included a sulphonylurea,
mild/moderate prevalence was 30% and incidence 2 events per person-year, and
severe prevalence was 5% and incidence 0.01 events per person-year. A similar
prevalence of 5% was found for treatment regimes that did not include
sulphonylureas.
Conclusions: Current evidence shows hypoglycaemia is considerably prevalent
amongst people with type 2 diabetes, particularly for those on insulin, yet still fairly
common for other treatment regimens. This highlights the subsequent need for educational interventions and individualisation of therapies to reduce the risk of
hypoglycaemia.
Funding
The authors acknowledge support from the National Institute for Health Research
Collaboration for Leadership in Applied Health Research and Care – East Midlands
(NIHR CLAHRC – EM), the Leicester Clinical Trials Unit and the NIHR LeicesterLoughborough
Diet, Lifestyle and Physical Activity Biomedical Research Unit which
is a partnership between University Hospitals of Leicester NHS Trust, Loughborough
University and the University of Leicester.
History
Citation
Diabetic Medicine, 2015, 32 (Suppl.) , pp. 22-23
Author affiliation
/Organisation/COLLEGE OF MEDICINE, BIOLOGICAL SCIENCES AND PSYCHOLOGY/School of Medicine/Department of Cardiovascular Sciences
Source
Abstracts of the Diabetes UK Professional Conference, 11–13 March 2015